The role of AXL in radioresistant and checkpoint immune-resistant tumours has been described, and the mechanism is thought to involve the ability of AXL to suppress antigen presentation through MHC-I and to enhance myeloid-supporting cytokines and chemokines, resulting in a limited initial immune response [133]. Here, AXL is linked to neoplasm.